The global market for Diarrhea-Dominant Irritable Bowel Syndrome (IBS-D) drugs is thoroughly examined in this research report. It provides a comprehensive analysis of market trends, growth drivers, and challenges, offering a detailed understanding of the sector’s developments and future prospects. The report covers market dynamics, segmentation, regional analysis, and competitive landscape assessment, presenting a comprehensive overview of the industry.
According to the report, the global IBS-D drugs market was valued at USD 3.3 billion in 2020 and is projected to reach USD 4.6 billion by the end of 2027, with a CAGR of 4.5% during the forecast period. The market growth is primarily driven by the increasing prevalence of IBS-D, rising healthcare expenditure, and growing awareness of available treatment options.
The report highlights major players operating in the global IBS-D drugs market, including Allergan plc., Valeant Pharmaceuticals International Inc., GlaxoSmithKline Plc., Sebela Pharmaceuticals Inc., Abbott Laboratories, Ardelyx Inc., Astellas Pharma Inc., AstraZeneca Plc., Synthetic Biologics Inc., and RedHill Biopharma Ltd. These companies are focused on product development and collaborations to expand their market presence and meet the rising demand for IBS-D drugs.
The report identifies significant growth potential in the IBS-D drug market due to factors such as the increasing global incidence of IBS-D, growing awareness of gastrointestinal disorders, and advancements in pharmaceutical R&D. Consequently, the demand for effective treatment options has surged, driving market expansion.
While the pharmaceutical market for IBS-D is still in its early stages, it shows promise, particularly with the introduction of proprietary medicines. This has stimulated further research and development, leading to the emergence of new treatment alternatives and market players.
Key market players mentioned in the report are Astellas Pharmaceuticals, Actavis, Pfizer, GlaxoSmithKline, Salix Pharmaceuticals, AstraZeneca, Ironwood Pharmaceuticals, Allergan, Takeda Pharmaceutical, Sebela Pharmaceuticals, Synergy Pharmaceuticals, Synthetic Biologics, and Bausch Health. These companies are focusing on acquisitions, partnerships, and new product launches to increase their market share and expand their geographical presence.
Download The Sample Report Here – https://www.credenceresearch.com/report/irritable-bowel-syndrome-ibs-with-diarrhea-drugs-market
The report provides a comprehensive analysis of the regional landscape of the global IBS-D drugs market, with North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa being the key regions. North America dominates the market due to factors such as a high prevalence of IBS-D, favorable reimbursement policies, and advanced healthcare infrastructure. However, the Asia Pacific region is expected to witness rapid growth during the forecast period due to increasing healthcare expenditure and rising awareness of IBS-D treatment options.
Furthermore, the study examines several drugs for IBS-D management, including Eluxadoline, Rifaximin, Alosetron, Loperamide, Diphenoxylate & Atropine, and Dicyclomine & Hyoscyamine. The report provides market size, forecasts, and Compound Annual Growth Rates (CAGRs) for these medicines from 2022 to 2028, using 2021 as the base year.
The IBS-D pharmaceutical market is divided into prescription and over-the-counter (OTC) categories based on prescription requirements. Within the prescription category, the group is further divided into branded and generic medicines. Market size and CAGRs for these divisions are provided from 2022 to 2028.
In addition, the report offers a geographical breakdown of the global IBS-D medication market, including North America, Europe, Asia Pacific, and the Rest of the World. Each region is further analyzed at the country-level market.
The analysis also discusses qualitative dimensions, such as market drivers, barriers, opportunities, investment propositions, and competitive analysis through fractal map analysis. It concludes by profiling dominant market entities involved in the production of IBS-D medicines.
What Will You Get in the Frozen Bakery Products Market Report?
The Frozen Bakery Products Market Report would typically provide an in-depth understanding and meticulous analysis of the global market landscape for frozen bakery items, similar to the comprehensive insights provided in the analysis of the IBS-D drugs market. Below are some aspects that one might expect to be covered in the Frozen Bakery Products Market Report:
Market Overview
Market Dynamics
Market Segmentation
Competitive Landscape
Regional Analysis
Future Market Projections
Research Methodology
Unlock the Full Insights! Access the Complete Report on Global IBS-D drugs market (2018-2028) Now.
Recently Published Report –
Flame Resistant Fabrics Market
Micro Irrigation Systems Market
About Us:
Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.
Media ContactCompany Name: Credence ResearchContact Person: Gunakesh ParmarEmail: Send EmailPhone: +91 6232493207City: GwaliorState: MPCountry: IndiaWebsite: https://www.credenceresearch.com/report/irritable-bowel-syndrome-ibs-with-diarrhea-drugs-market